Medical specialists from Tanzania tagged as investigators in clinical trials studying Infections

Total 5 results

Ally Olotu, PhD
Seen in:
- Pwani, Bagamoyo, Bagamoyo District Hospital
Trials:
- NCT05881447 (Principal Investigator)
Conditions:
- Cardiovascular Diseases;
- HIV Infections;
- Infections;
- Obesity;
- Chronic Kidney Diseases;
- Type 2 Diabetes Mellitus;
- Anemia;
- Dyslipidemias;
- Albuminuria;
- Arterial Hypertension;
- Underweight
Humphrey D Mazigo
Seen in:
- Lake Victoria Zone, Mwanza, Ilemela District
Trials:
- NCT01541631 (Principal Investigator)
Conditions:
Kandy Lussingu, MD
Seen in:
- Pwani, Bagamoyo, Bagamoyo District Hospital
Trials:
- NCT05881447 (Sub-Investigator)
Conditions:
- Cardiovascular Diseases;
- HIV Infections;
- Infections;
- Obesity;
- Chronic Kidney Diseases;
- Type 2 Diabetes Mellitus;
- Anemia;
- Dyslipidemias;
- Albuminuria;
- Arterial Hypertension;
- Underweight
Nikolai C Hodel, MSc
Seen in:
- Pwani, Bagamoyo, Bagamoyo District Hospital
Trials:
- NCT05881447 (Sub-Investigator)
Conditions:
- Cardiovascular Diseases;
- HIV Infections;
- Infections;
- Obesity;
- Chronic Kidney Diseases;
- Type 2 Diabetes Mellitus;
- Anemia;
- Dyslipidemias;
- Albuminuria;
- Arterial Hypertension;
- Underweight
Rudovick Kazwala, PhD
Seen in:
- Iringa, Iringa
Trials:
- NCT05139524 (Principal Investigator)
Conditions:
- Hemorrhagic Fevers, Viral;
- Rift Valley Fever

Clinical Trials on Infections

International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention

Not yet recruiting

Co-administration Study of OCV, TCV and MR

Measles | Rubella | Cholera | Typhoid
MJM Bonten
Janssen Research & Development, LLC; Innovative Medicines Initiative

Completed

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1) (EXPECT-1)

E.Coli Infections

United States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
Pfizer

Completed

Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants

Group B Streptococcus Infections

United States, South Africa, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Infections, Meningococcal

Finland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
Pfizer

Completed

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

Infections, Meningococcal

Australia, Canada, Czechia, Panama, South Africa, Turkey
GlaxoSmithKline

Completed

Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children

Infections, Meningococcal

Finland
Pfizer

Completed

Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination

Infections, Meningococcal

Philippines
GlaxoSmithKline

Completed

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Infections, Meningococcal

United States, Finland, Poland
Pfizer

Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Infections, Meningococcal

Finland
GlaxoSmithKline

Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

Infections, Meningococcal

Australia

Subscribe